Whole Blood Biospecimen Collection for Subjects With Chronic Granulomatous Disease (CGD)

Sanguine Biosciences6 enrolled

Overview

The primary study objective is to collect biospecimen samples (e.g., blood) from participants diagnosed with Chronic Granulomatous Disease (CGD). The biospecimens will be used to create a biorepository that can be used to identify disease associated biomarkers and potential targets with immune and multi-omics profiling. The disease sample collection and analysis will be the foundation for an extensive network of biospecimen access and linked datasets for future translational research.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Chronic Granulomatous Disease

Interventions

Specimen DonationDIAGNOSTIC_TEST

blood donation

Eligibility

Sex: ALLMin age: 18 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: * The participant is willing and able to provide written informed consent * The participant is willing and able to provide appropriate photo identification * Participants aged 18 to 85 * Participants have been diagnosed with Chronic Granulomatous Disease (CGD) * Subjects who have a confirmed p47phox CGD mutation or Subjects who have a confirmed X-linked CGD mutation Exclusion Criteria: * Participants who are pregnant or are nursing * Participants with a known history of HIV, hepatitis, or other infectious diseases * Participants who have taken an investigational product in the last 30 days * Participants who have experienced excess blood loss, including blood donation, defined as 250 mL in the last month or 500 mL in the previous two months

Locations (1)

Sanguine BioSciences, Inc.

Woburn, Massachusetts, United States

Outcomes

Primary Outcomes

Participants have been diagnosed with Chronic Granulomatous Disease (CGD)

Time frame: 1 Year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.